Fig. 4
Dose-response curves and colony formation of cells treated with RALA/ALN NPs. a LN229 and b T98G glioblastoma cancer cells were treated with uncomplexed ALN to achieve a final concentration ranging from 5 μM to 1 mM and RALA/ALN NPs were prepared at a 10:1 mass ratio such that the final concentration of ALN per well ranged between 5 μM to 75 μM. Cells were treated for 6 h before medium was replaced with complete media and left to incubate for 72 h. Cell viability was assessed using MTS reagent and expressed as a percentage of the untreated control (considered to be 100% viable). The IC50 values were calculated using commercial software (GraphPad Prism® 8.1.2, GraphPad Software, USA). Data were obtained from three repeat MTS experiments. Clonogenic survival assay in c LN229 and d T98G cells treated with RALA/ALN NPs. Cells were treated for 6 h with uncomplexed ALN and RALA/ALN NPs prepared at mass ratio 10:1 to achieve a final ALN concentration of 43.83 μM and 60.55 μM in T98G and LN229 cell lines, respectively. The SF was calculated as the plating efficiency of the treated groups divided by the plating efficiency of untreated cells. Results are reported as mean ± SEM, n = 3